Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 4/2021

12.10.2020 | Original Paper

A Randomized Trial Comparing Brief Advice and Motivational Interviewing for Persons with HIV–HCV Co-infection Who Drink Alcohol

verfasst von: Michael D. Stein, Debra S. Herman, H. Nina Kim, Abigail Howell, Audrey Lambert, Stephanie Madden, Ethan Moitra, Claire E. Blevins, Bradley J. Anderson, Lynn E. Taylor, Megan M. Pinkston

Erschienen in: AIDS and Behavior | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Alcohol use contributes to the progression of liver disease in HIV–HCV co-infected persons, but alcohol interventions have never addressed low levels of alcohol use in this population. We enrolled 110 persons consuming at least 4 alcoholic drinks weekly in a clinical trial comparing two active 18-month long interventions, delivered every 3 months by phone, brief advice about drinking versus a motivational intervention. Final assessment was at 24 months. MI had larger reductions in alcohol use days than the BA arm at all follow-up assessments. The treatment by time effect was not significant for days of drinking (p = 0.470), mean drinks per day (p = 0.155), or for the continuous FIB-4 index (p = 0.175). Drinking declined in both conditions from baseline, but given the small sample, we do not have sufficient data to make any conclusion that one treatment is superior to the other.
Trial Registry Trial registered at clinicaltrials.gov; Clinical Trial NCT02316184.
Literatur
1.
Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int. 2010;30(7):1012–8.PubMedCrossRef
2.
Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32(3):492–7.PubMedCrossRef
3.
4.
Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–29.PubMedCrossRef
5.
Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study Lancet. 1999;353(9156):863–8.
6.
May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368(9534):451–8.PubMedCrossRef
7.
Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS ONE. 2011;6(7):e22698.PubMedPubMedCentralCrossRef
8.
Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med. 2009;10(5):282–9.PubMedCrossRef
9.
Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D study. Arch Intern Med. 2006;166(15):1632–41.PubMedCrossRef
10.
Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol. 2005;3(11):1150–9.PubMedCrossRef
11.
Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology. 2002;36(5 Suppl 1):S220–S22525.PubMed
12.
13.
14.
Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979–91.PubMedCrossRef
15.
Ferguson TF, Rosen E, Carr R, Brashear M, Simon L, Theall KP, et al. Associations of liver disease with alcohol use among people living with HIV and the role of hepatitis C: the New Orleans alcohol use in HIV study. Alcohol Alcohol. 2020;55(1):28–36.PubMedCrossRef
16.
Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA. 2002;99(24):15661–8.PubMedCrossRefPubMedCentral
17.
McCartney EM, Beard MR. Impact of alcohol on hepatitis C virus replication and interferon signaling. World J Gastroenterol. 2010;16(11):1337–433.PubMedPubMedCentralCrossRef
18.
Seronello S, Ito C, Wakita T, Choi J. Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+. J Biol Chem. 2010;285(2):845–54.PubMedCrossRef
19.
Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41(6):845–50.PubMedPubMedCentralCrossRef
20.
Castellano-Higuera A, Gonzalez-Reimers E, Aleman-Valls MR, Abreu-Gonzalez P, Santolaria-Fernandez F, De La Vega-Prieto MJ, et al. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol Alcohol. 2008;43(2):137–42.PubMedCrossRef
21.
22.
Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–744.PubMedCrossRef
23.
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.PubMedCrossRef
24.
Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63(2):179–86.PubMedCrossRef
25.
Stoller EP, Hund AJ, Webster NJ, Blixen CE, Perzynski AT, McCormick RA, et al. Alcohol consumption within the context of hepatitis C: a qualitative study of non-problematic drinkers. Alcohol Alcohol. 2006;41(5):546–52.PubMedCrossRef
26.
Crane HM, McCaul ME, Chander G, Hutton H, Nance RM, Delaney JAC, et al. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. AIDS Behav. 2017;21(7):1914–25.PubMedPubMedCentralCrossRef
27.
Kahler CW, Liu T, Cioe PA, Bryant V, Pinkston MM, Kojic EM, et al. Direct and indirect effects of heavy alcohol use on clinical outcomes in a longitudinal study of HIV patients on ART. AIDS Behav. 2017;21(7):1825–35.PubMedPubMedCentralCrossRef
28.
Hartzler B, Dombrowski JC, Crane HM, Eron JJ, Geng EH, Christopher Mathews W, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. AIDS Behav. 2017;21(4):1138–48.PubMedPubMedCentralCrossRef
29.
Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol. 2000;95(3):740–7.PubMedCrossRef
30.
Fireman M, Indest DW, Blackwell A, Whitehead AJ, Hauser P. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis. 2005;40(Suppl 5):S286–S291291.PubMedCrossRef
31.
Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34(3):268–71.PubMedCrossRef
32.
Chander G, Josephs J, Fleishman JA, Korthuis PT, Gaist P, Hellinger J, et al. Alcohol use among HIV-infected persons in care: results of a multi-site survey. HIV Med. 2008;9(4):196–202.PubMedPubMedCentralCrossRef
33.
Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.PubMedPubMedCentralCrossRef
34.
Conen A, Fehr J, Glass TR, Furrer H, Weber R, Vernazza P, et al. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Ther. 2009;14(3):349–57.
35.
Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83–8.PubMedPubMedCentralCrossRef
36.
Justice AC, Lasky E, McGinnis KA, Skanderson M, Conigliaro J, Fultz SL, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care. 2006;44(8 Suppl 2):S52–60.PubMedCrossRef
37.
Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. 2007;46(2):194–9.PubMedPubMedCentralCrossRef
38.
Scott-Sheldon LAJ, Carey KB, Johnson BT, Carey MP. Behavioral interventions targeting alcohol use among people living with HIV/AIDS: a systematic review and meta-analysis. AIDS Behav. 2017;21(Suppl 2):126–43.PubMedPubMedCentralCrossRef
39.
Hasin DS, Aharonovich E, O'Leary A, Greenstein E, Pavlicova M, Arunajadai S, et al. Reducing heavy drinking in HIV primary care: a randomized trial of brief intervention, with and without technological enhancement. Addiction. 2013;108(7):1230–40.PubMedPubMedCentralCrossRef
40.
Chander G, Hutton HE, Lau B, Xu X, McCaul ME. Brief intervention decreases drinking frequency in HIV-infected, heavy drinking women: results of a randomized controlled trial. J Acquir Immune Defic Syndr. 2015;70(2):137–45.PubMedPubMedCentralCrossRef
41.
Kahler CW, Pantalone DW, Mastroleo NR, Liu T, Bove G, Ramratnam B, et al. Motivational interviewing with personalized feedback to reduce alcohol use in HIV-infected men who have sex with men: a randomized controlled trial. J Consult Clin Psychol. 2018;86(8):645–56.PubMedPubMedCentralCrossRef
42.
Satre DD, Leibowitz AS, Leyden W, Catz SL, Hare CB, Jang H, et al. Interventions to reduce unhealthy alcohol use among primary care patients with HIV: the health and motivation randomized clinical trial. J Gen Intern Med. 2019;34(10):2054–61.PubMedPubMedCentralCrossRef
43.
Proeschold-Bell RJ, Evon DM, Yao J, Niedzwiecki D, Makarushka C, Keefe KA, et al. A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection. Hepatology. 2020;71(6):1894–909.PubMedCrossRef
44.
Ballesteros J, Duffy JC, Querejeta I, Arino J, Gonzalez-Pinto A. Efficacy of brief interventions for hazardous drinkers in primary care: systematic review and meta-analyses. Alcohol Clin Exp Res. 2004;28(4):608–18.PubMedCrossRef
45.
Bertholet N, Daeppen JB, Wietlisbach V, Fleming M, Burnand B. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch Intern Med. 2005;165(9):986–95.PubMedCrossRef
46.
Moyer A, Finney JW, Swearingen CE, Vergun P. Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction. 2002;97(3):279–92.PubMedCrossRef
47.
Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(7):557–68.PubMedCrossRef
48.
Saunders JB, Lee NK. Hazardous alcohol use: its delineation as a subthreshold disorder, and approaches to its diagnosis and management. Compr Psychiatry. 2000;41(2 Suppl 1):95–103.PubMedCrossRef
49.
Kaner EF, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007;2:4148.
50.
Stein MD, Weinstock MC, Herman DS, Anderson BJ, Anthony JL, Niaura R. A smoking cessation intervention for the methadone-maintained. Addiction. 2006;101(4):599–607.PubMedCrossRef
51.
Moyers T, Manuel JK, Ernst D. Motivational Interviewing Treatment Integrity Coding Manual 4.1. Unpublished Manual. 2014.
52.
McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Mental Dis. 1980;168(1):26–33.CrossRef
53.
Sobell L, Sobell M. Timeline Followback user's guide: a calendar method for assessing alcohol and drug use. Toronto: Addiction Research Foundation; 1996.
54.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.PubMedCrossRef
55.
Raftery AE. Bayesian model selection in social research. Sociol Methodol. 1995;25:111–63.CrossRef
56.
Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abus. 2007;28(3):7–30.PubMedCrossRef
57.
Aalto M, Saksanen R, Laine P, Forsstrom R, Raikaa M, Kiviluoto M, et al. Brief intervention for female heavy drinkers in routine general practice: a 3-year randomized, controlled study. Alcohol Clin Exp Res. 2000;24(11):1680–6.PubMedCrossRef
58.
Aalto M, Seppa K, Mattila P, Mustonen H, Ruuth K, Hyvarinen H, et al. Brief intervention for male heavy drinkers in routine general practice: a three-year randomized controlled study. Alcohol Alcohol. 2001;36(3):224–30.PubMedCrossRef
59.
Kaner E, Bland M, Cassidy P, Coulton S, Dale V, Deluca P, et al. Effectiveness of screening and brief alcohol intervention in primary care (SIPS trial): pragmatic cluster randomised controlled trial. BMJ. 2013;346:e8501.PubMedPubMedCentralCrossRef
60.
Edwards AG, Rollnick S. Outcome studies of brief alcohol intervention in general practice: the problem of lost subjects. Addiction. 1997;92(12):1699–704.PubMedCrossRef
61.
Jonas DE, Garbutt JC, Amick HR, Brown JM, Brownley KA, Council CL, et al. Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2012;157(9):645–54.PubMedCrossRef
62.
McKay J. Is there a case for extended interventions for alcohol and drug use disorders? Addiction. 2005;100(11):1594–610.PubMedCrossRef
63.
DeLorenze GN, Weisner C, Tsai AL, Satre DD, Quesenberry CP Jr. Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program. Alcohol Clin Exp Res. 2011;35(2):203–10.PubMedCrossRef
64.
Shuper PA, Joharchi N, Irving H, Rehm J. Alcohol as a correlate of unprotected sexual behavior among people living with HIV/AIDS: review and meta-analysis. AIDS Behav. 2009;13(6):1021–36.PubMedCrossRef
65.
Williams EC, McGinnis KA, Edelman EJ, Matson TE, Gordon AJ, Marshall BDL, et al. Level of alcohol use associated with HIV care continuum targets in a national US sample of persons living with HIV receiving healthcare. AIDS Behav. 2019;23(1):140–51.PubMedPubMedCentralCrossRef
66.
Metsch LR, Pereyra M, Colfax G, Dawson-Rose C, Cardenas G, McKirnan D, et al. HIV-positive patients' discussion of alcohol use with their HIV primary care providers. Drug Alcohol Depend. 2008;95(1–2):37–44.PubMedCrossRef
67.
Strauss SM, Munoz-Plaza CE, Tiburcio NJ, Gwadz M. Barriers and facilitators in implementing "prevention for positives" alcohol-reduction support: the perspectives of directors and providers in hospital-based HIV care centers. J Assoc Nurs AIDS Care. 2012;23(1):30–40.CrossRef
68.
Strauss SM, Tiburcio NJ, Munoz-Plaza C, Gwadz M, Lunievicz J, Osborne A, et al. HIV care providers' implementation of routine alcohol reduction support for their patients. AIDS Patient Care STDs. 2009;23(3):211–8.PubMedPubMedCentralCrossRef
69.
Aharonovich E, Hatzenbuehler ML, Johnston B, O'Leary A, Morgenstern J, Wainberg ML, et al. A low-cost, sustainable intervention for drinking reduction in the HIV primary care setting. AIDS Care. 2006;18(6):561–8.PubMedCrossRef
70.
Armstrong ML, LaPlante AM, Altice FL, Copenhaver M, Molina PE. Advancing behavioral HIV prevention: adapting an evidence-based intervention for people living with HIV and alcohol use disorders. AIDS Res Treat. 2015;2015:879052.PubMedPubMedCentral
71.
Miller WR, Baca C, Compton WM, Ernst D, Manuel JK, Pringle B, et al. Addressing substance abuse in health care settings. Alcohol Clin Exp Res. 2006;30(2):292–302.PubMedCrossRef
72.
Saitz R. Alcohol screening and brief intervention in primary care: absence of evidence for efficacy in people with dependence or very heavy drinking. Drug Alcohol Rev. 2010;29(6):631–40.PubMedPubMedCentralCrossRef
Metadaten
Titel
A Randomized Trial Comparing Brief Advice and Motivational Interviewing for Persons with HIV–HCV Co-infection Who Drink Alcohol
verfasst von
Michael D. Stein
Debra S. Herman
H. Nina Kim
Abigail Howell
Audrey Lambert
Stephanie Madden
Ethan Moitra
Claire E. Blevins
Bradley J. Anderson
Lynn E. Taylor
Megan M. Pinkston
Publikationsdatum
12.10.2020
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 4/2021
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-03062-2

Weitere Artikel der Ausgabe 4/2021

AIDS and Behavior 4/2021 Zur Ausgabe

Original Paper

Transactional Sex, Alcohol Use and Intimate Partner Violence Against Women in the Rakai Region of Uganda

Original Paper

Opportunities to Harness Technology to Deliver HIV Prevention / Healthy Sexuality Programming to Sexual and Gender Minority Adults Living in East Africa

Original Paper

DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men

Original Paper

Examining the Influence of Trauma Exposure on HIV Sexual Risk Between Men and Women in Post-Conflict Liberia

Original Paper

A Dyadic Analysis of Criminal Justice Involvement and Sexual HIV Risk Behaviors Among Drug-Involved Men in Community Corrections and Their Intimate Partners in New York City: Implications for Prevention, Treatment and Policies

Original Paper

TRUST: Assessing the Efficacy of an Intervention to Increase HIV Self-Testing Among Young Black Men Who have Sex with Men (MSM) and Transwomen

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise